EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products

The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.